Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
MSTR · Nasdaq · United States · Finance Services
In shortStrategy Inc is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it. Bank or insurer: tests that do not apply to them are left out.
| Operating marginShare of each sale left after running the business, before interest and tax. | -1140.8% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -806.3% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -10.2% | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -15.8% | n/a |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 3 of 5 | n/a |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 4.9% | 93/100 |
| Operating margin volatility | 439.4% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -1.5% | 8/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 511 | 499 | 496 | 463 | 477 |
| Cost of revenue | 92 | 103 | 110 | 129 | 149 |
| Gross profit | 419 | 396 | 386 | 334 | 328 |
| Research & development | 117 | 127 | 121 | 118 | 94 |
| Operating income | (785) | (1,276) | (115) | (1,853) | (5,444) |
| Pre-tax income | (811) | (1,322) | (125) | (1,934) | (5,526) |
| Income tax | (276) | 147 | (554) | (768) | (1,678) |
| Net income | (535) | (1,470) | 429 | (1,167) | (3,848) |
| Diluted EPS | −$53.44 | −$12.98 | $2.64 | −$6.06 | −$15.23 |
| Diluted shares (millions) | 10 | 113 | 166 | 193 | 278 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
Not computed: the model does not apply to banks and insurers.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 3, 2026